Abstract

Inhibitor of apoptosis (IAP) proteins are frequently expressed at high levels in cancer cells and represent attractive therapeutic targets. We previously reported that the Smac (second mitochondria-derived activator of caspases) mimetic BV6, which antagonizes IAP proteins, sensitizes glioblastoma cells to temozolomide (TMZ)-induced cell death in a nuclear factor-κB (NF-κB)-dependent manner. However, BV6-induced NF-κB target genes responsible for this synergistic interaction have remained elusive. Using whole-genome gene expression profiling, we here identify BV6-stimulated, NF-κB-dependent transcriptional upregulation of interferon-β (IFNβ) and IFN-mediated proapoptotic signaling as critical events that mediate BV6/TMZ-induced apoptosis. Knockdown of IFNβ significantly rescues cells from BV6/TMZ-induced cell death. Similarly, silencing of the corresponding receptor IFNα/β receptor (IFNAR) confers a significant protection against apoptosis, demonstrating that IFNβ and IFN signaling are required for BV6/TMZ-mediated cell death. Moreover, BV6 and TMZ cooperate to transcriptionally upregulate the proapoptotic B-cell lymphoma 2 family proteins Bax (Bcl-2-associated X protein) or Puma (p53-upregulated modulator of apoptosis). Knockdown of Bax or Puma significantly decreases BV6/TMZ-induced apoptosis, showing that both proteins are necessary for apoptosis. By identifying IFNβ as a key mediator of BV6/TMZ-induced apoptosis, our study provides novel insights into the underlying molecular mechanisms of Smac mimetic-mediated chemosensitization with important implications for the development of novel treatment strategies for glioblastoma.

Highlights

  • Evasion of programmed cell death is one of the hallmarks of human cancers[3] and promotes tumorigenesis as well as treatment resistance.[4]

  • We assessed cell death upon treatment with the chemotherapeutic agent TMZ and the second mitochondria-derived activator of caspases (Smac) mimetic BV6 using the glioblastoma cell lines A172 and T98G to confirm that Smac mimetic enhances TMZ-induced apoptosis, as we reported previously.[12]

  • We previously reported nuclear factor-κB (NF-κB)-dependent sensitization of glioblastoma cells to TMZ-induced apoptosis by the Smac mimetic BV6 as a novel approach to enhance the efficacy of conventional chemotherapy in glioblastoma.[12]

Read more

Summary

Introduction

Evasion of programmed cell death is one of the hallmarks of human cancers[3] and promotes tumorigenesis as well as treatment resistance.[4] Apoptosis is a common form of programmed cell death that can be engaged via the intrinsic (mitochondrial) or extrinsic (death receptor) pathway.[5] Activation of the intrinsic pathway is controlled by pro- and antiapoptotic B-cell lymphoma 2 (Bcl-2) family protein, including Bcl-2 family proteins such as p53-upregulated modulator of apoptosis (Puma) or Bcl-2-associated X protein (Bax). Following engagement of the mitochondrial pathway, mitochondrial intermembrane space proteins are released into the cytosol, including second mitochondria-derived activator of caspases (Smac).[6] Smac binds to and neutralizes Inhibitor of Apoptosis (IAP) proteins, a family of antiapoptotic proteins, thereby promoting activation of caspases and apoptosis.[7]. We aimed at discovering novel NF-κB-dependent factors that are required for the cooperative anticancer activity of BV6 and TMZ, the prototypic chemotherapeutic agent used for the treatment of glioblastoma

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.